INOVIO PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
INOVIO PHARMACEUTICALS INC. - More news...
INOVIO PHARMACEUTICALS INC. - More news...
- INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
- INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
- INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- INOVIO Reports Inducement Grant Under Inducement Plan
- INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split
- INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader
- INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
- INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program
- INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights
- INOVIO Reports Inducement Grants Under Inducement Plan
- INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023
- INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program
- INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
- INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update
- INOVIO Reports Inducement Grants Under Inducement Plan
- INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023
- INOVIO Reports Inducement Grants Under Inducement Plan
- INOVIO to Present at the 2023 Jefferies Healthcare Conference
- INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
- INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights
- New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
- INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference
- INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023
- INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023
- European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107
- Data from Phase 1b trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) presented at ECCMID 2023
- INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023